BACKGROUND:Infliximab is effective treatment for Crohn's disease and has been associated with rare, but serious infectious complications. Emerging data suggest a benefit of infliximab in preventing postoperative Crohn's disease recurrence. It is not known whether administration of infliximab shortly after resective surgery for Crohn's disease increases postoperative complications. AIMS: To evaluate the risk of developing postoperative complications among Crohn's disease patients receiving infliximab within 4 weeks of intestinal resection. METHODS: As part of a randomized placebo-controlled infliximab postoperative prevention study, adverse events were prospectively monitored. Crohn's disease patients undergoing intestinal resection were randomized to placebo or infliximab 2-4 weeks after surgery. Study infusions were administered at 0, 2, and 6 weeks then every 8 weeks for 1 year. To evaluate whether infliximab increased postoperative complications, we analyzed all adverse events for 1 year after surgery. RESULTS: Twenty-four patients were randomized to infliximab or placeboafter intestinal resection for Crohn's disease. Mean time to first postoperative infusion was 20 days (range 14-25 days). Over the course of 1 year, there were 22 total adverse events, but no difference between infliximab and placebo patients (12 versus 10, respectively, P = 1.0). In the immediate postoperative period, within 8 weeks of surgery, the number of adverse events was also similar between the two groups (3 infliximab and 5 placebo patients, P = 0.68). There were no serious adverse events and no complications related to wound healing or infection. CONCLUSIONS: Initiation of infliximab within 4 weeks of intestinal resection was not associated with postoperative complications.
RCT Entities:
BACKGROUND:Infliximab is effective treatment for Crohn's disease and has been associated with rare, but serious infectious complications. Emerging data suggest a benefit of infliximab in preventing postoperative Crohn's disease recurrence. It is not known whether administration of infliximab shortly after resective surgery for Crohn's disease increases postoperative complications. AIMS: To evaluate the risk of developing postoperative complications among Crohn's diseasepatients receiving infliximab within 4 weeks of intestinal resection. METHODS: As part of a randomized placebo-controlled infliximab postoperative prevention study, adverse events were prospectively monitored. Crohn's diseasepatients undergoing intestinal resection were randomized to placebo or infliximab 2-4 weeks after surgery. Study infusions were administered at 0, 2, and 6 weeks then every 8 weeks for 1 year. To evaluate whether infliximab increased postoperative complications, we analyzed all adverse events for 1 year after surgery. RESULTS: Twenty-four patients were randomized to infliximab or placebo after intestinal resection for Crohn's disease. Mean time to first postoperative infusion was 20 days (range 14-25 days). Over the course of 1 year, there were 22 total adverse events, but no difference between infliximab and placebo patients (12 versus 10, respectively, P = 1.0). In the immediate postoperative period, within 8 weeks of surgery, the number of adverse events was also similar between the two groups (3 infliximab and 5 placebo patients, P = 0.68). There were no serious adverse events and no complications related to wound healing or infection. CONCLUSIONS: Initiation of infliximab within 4 weeks of intestinal resection was not associated with postoperative complications.
Authors: L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts Journal: Aliment Pharmacol Ther Date: 2004-04-01 Impact factor: 8.171
Authors: Miguel Regueiro; Wolfgang Schraut; Leonard Baidoo; Kevin E Kip; Antonia R Sepulveda; Marilyn Pesci; Janet Harrison; Scott E Plevy Journal: Gastroenterology Date: 2008-10-31 Impact factor: 22.682
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton Journal: J Am Coll Surg Date: 2007-05 Impact factor: 6.113
Authors: Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran Journal: J Gastrointest Surg Date: 2008-08-15 Impact factor: 3.452
Authors: Stefanie J Schluender; Andrew Ippoliti; Marla Dubinsky; Eric A Vasiliauskas; Konstantinos A Papadakis; Ling Mei; Stephan R Targan; Phillip R Fleshner Journal: Dis Colon Rectum Date: 2007-11 Impact factor: 4.585
Authors: Zipporah Iheozor-Ejiofor; Morris Gordon; Andrew Clegg; Suzanne C Freeman; Teuta Gjuladin-Hellon; John K MacDonald; Anthony K Akobeng Journal: Cochrane Database Syst Rev Date: 2019-09-12
Authors: Christine A Schad; Bryce E Haac; Raymond K Cross; Ali Syed; Shumet Lonsako; Andrea C Bafford Journal: Dig Dis Sci Date: 2019-01-25 Impact factor: 3.487
Authors: Brent L Cao; Ahmad Qasem; Robert C Sharp; Latifa S Abdelli; Saleh A Naser Journal: World J Gastroenterol Date: 2018-07-07 Impact factor: 5.742